BR112016002721A2 - peptídeos capazes de reativar p53 mutantes - Google Patents

peptídeos capazes de reativar p53 mutantes

Info

Publication number
BR112016002721A2
BR112016002721A2 BR112016002721-3A BR112016002721A BR112016002721A2 BR 112016002721 A2 BR112016002721 A2 BR 112016002721A2 BR 112016002721 A BR112016002721 A BR 112016002721A BR 112016002721 A2 BR112016002721 A2 BR 112016002721A2
Authority
BR
Brazil
Prior art keywords
peptides
mutant
reactivating
peptides capable
reactivating mutant
Prior art date
Application number
BR112016002721-3A
Other languages
English (en)
Portuguese (pt)
Inventor
Oren Moshe
Rotter Varda
Tal Perry
Original Assignee
Yeda Research And Development Company Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Research And Development Company Ltd. filed Critical Yeda Research And Development Company Ltd.
Publication of BR112016002721A2 publication Critical patent/BR112016002721A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4746—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
BR112016002721-3A 2013-08-07 2014-08-07 peptídeos capazes de reativar p53 mutantes BR112016002721A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361862977P 2013-08-07 2013-08-07
US61/862,977 2013-08-07
PCT/IB2014/063777 WO2015019318A1 (en) 2013-08-07 2014-08-07 Peptides capable of reactivating p53 mutants

Publications (1)

Publication Number Publication Date
BR112016002721A2 true BR112016002721A2 (pt) 2018-07-10

Family

ID=52460737

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016002721-3A BR112016002721A2 (pt) 2013-08-07 2014-08-07 peptídeos capazes de reativar p53 mutantes

Country Status (12)

Country Link
US (4) US9856289B2 (https=)
EP (1) EP3030571B1 (https=)
JP (2) JP6554099B2 (https=)
CN (1) CN105579464B (https=)
AU (2) AU2016200713B2 (https=)
BR (1) BR112016002721A2 (https=)
CA (1) CA2920147C (https=)
ES (1) ES2795982T3 (https=)
HU (1) HUE049292T2 (https=)
IL (2) IL243944B (https=)
RU (2) RU2693487C2 (https=)
WO (1) WO2015019318A1 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE049292T2 (hu) 2013-08-07 2020-09-28 Yeda Res & Dev A P53 mutánsok újraaktíválására képes peptidek
CN105112377B (zh) * 2015-09-25 2018-10-30 福州迈新生物技术开发有限公司 一株分泌抗p53单克隆抗体的杂交瘤细胞株及其应用
CN108884137B (zh) * 2016-02-04 2022-04-05 耶达研究及发展有限公司 肽及其在治疗与突变型p53相关的疾病、病症或病况中的用途
US20220251159A1 (en) * 2016-02-04 2022-08-11 Yeda Research And Development Co., Ltd Peptides and use of same in the treatment of diseases, disroders or conditions associated with a mutant p53
WO2019067243A1 (en) 2017-09-29 2019-04-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T CELL RECEPTORS RECOGNIZING P53 MUTE
EA202091396A1 (ru) 2017-12-07 2020-09-02 РИВЕН АйПи ХОЛДКО ЭлЭлСи Композиции и способы лечения метаболических состояний
EP3723785A1 (en) * 2017-12-17 2020-10-21 Yeda Research and Development Co. Ltd Cop9 signalosome (csn) complex modulators and uses thereof
WO2019134070A1 (en) * 2018-01-02 2019-07-11 Rui Jin Hospital, Shanghai Jiao Tong University School Of Medicine Panda as novel therapeutic
JP2022536708A (ja) * 2019-06-12 2022-08-18 リーベン アイピー ホールディングカンパニー リミテッド ライアビリティ カンパニー がん患者の予後を改善する方法および組成物
JP7402026B2 (ja) 2019-11-27 2023-12-20 株式会社小松製作所 作業機械の制御システム、作業機械、作業機械の制御方法
US20230127559A1 (en) 2020-03-16 2023-04-27 Yeda Research And Development Co. Ltd. Peptide analogs and use of same in treating diseases, disorders or conditions associated with mutant p53 protein
CN111574591B (zh) * 2020-04-29 2021-09-21 西安交通大学医学院第一附属医院 一种多肽及其合成方法
CN111686127B (zh) * 2020-06-04 2022-02-15 华南理工大学 锌铁纳米材料在降解突变p53蛋白中的应用
CN113750246B (zh) * 2020-06-04 2023-12-05 华南理工大学 ZIF-8纳米材料在降解广谱突变p53蛋白中的应用
US20230049952A1 (en) * 2020-06-24 2023-02-16 Pmv Pharmaceuticals, Inc. Methods and compounds for restoring mutant p53 function
CA3202616A1 (en) * 2020-12-21 2022-06-30 Alaunus Biosciences, Inc. Peptidase cleavable substrates and methods of identification and use thereof
CN112921032A (zh) * 2020-12-29 2021-06-08 苏州中科先进技术研究院有限公司 一种引物对、探针、试剂盒及其使用方法
CN115466786A (zh) * 2021-06-11 2022-12-13 上海交通大学医学院附属瑞金医院 一种筛选适合用p53复活药物治疗p53异常相关疾病病人的方法
WO2026008977A1 (en) * 2024-07-01 2026-01-08 Cambridge Enterprise Limited Protein aggregates

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5294605A (en) 1990-07-19 1994-03-15 The Scripps Research Institute Amphiphilic peptide compositions and analogues thereof
US5614393A (en) 1991-10-10 1997-03-25 Rhone-Poulenc Agrochimie Production of γ-linolenic acid by a Δ6-desaturase
US5969120A (en) * 1993-09-03 1999-10-19 Research Development Foundation Mutants of the RB and P53 genes
US6184205B1 (en) 1994-07-22 2001-02-06 University Of North Carolina At Chapel Hill GRB2 SH3 binding peptides and methods of isolating and using same
US6169073B1 (en) * 1995-02-16 2001-01-02 Bayer Corporation Peptides and peptidomimetics with structural similarity to human p53 that activate p53 function
US5877282A (en) 1996-09-20 1999-03-02 Bristol-Myers Squibb Company Peptide inhibitors of nuclear protein translocation having nuclear localization sequences and methods of use thereof
EP0989136A4 (en) * 1997-05-15 2002-10-09 Kyowa Hakko Kogyo Kk PEPTIDES WITH CYCLIC STRUCTURES THAT CAN RECOVER THE ACTIVITY OF MUTED P53 PROTEINS.
US20030224379A1 (en) * 2000-01-21 2003-12-04 Tang Y. Tom Novel nucleic acids and polypeptides
PT1377314E (pt) 2001-01-26 2012-01-02 Inhibitex Inc Anticorpos monoclonais para a proteína clfa e método de utilização no tratamento ou prevenção de infecções
EP1472276A4 (en) * 2001-02-28 2007-05-09 Keith M Skubitz PEPTIDES OF SMALL SIZE CAPACITY TO MODULATE THE FUNCTION OF THE MEMBERS OF THE FAMILY OF CD66 (CEACAM)
AU2003202689A1 (en) * 2002-01-23 2003-09-09 El-Gewely, Mohamed, Raafat Methods of screening molecular libraries for active molecules that restore the function of target proteins and peptides that restore the function of mutant p53
US7361747B2 (en) * 2003-05-22 2008-04-22 The University Of Hong Kong Isolation and characterization of the precursor virus of human SARS virus: SARS-associated corona virus-like virus
AU2006339072A1 (en) * 2005-03-14 2007-10-25 Board Of Regents Of The University Of Texas System Bioactive FUS1 peptides and nanoparticle-polypeptide complexes
WO2009094006A2 (en) * 2007-10-25 2009-07-30 Wake Forest University Health Sciences Bordetella outer-membrane protein antigens and methods of making and using the same
US8822420B2 (en) * 2008-03-13 2014-09-02 Universita Degli Studi Di Trieste Peptides and aptamers thereof as specific modulators of mutant p53 function
US8287845B2 (en) * 2008-12-18 2012-10-16 E I Du Pont De Nemours And Company Hair-binding peptides
WO2013040142A2 (en) * 2011-09-16 2013-03-21 Iogenetics, Llc Bioinformatic processes for determination of peptide binding
US9517252B2 (en) * 2011-09-09 2016-12-13 Agency For Science, Technology And Research p53 activating peptides
EP2895499B1 (en) * 2012-09-13 2019-04-10 Université de Genève Cell penetrating peptides
HUE049292T2 (hu) 2013-08-07 2020-09-28 Yeda Res & Dev A P53 mutánsok újraaktíválására képes peptidek
CN108884137B (zh) 2016-02-04 2022-04-05 耶达研究及发展有限公司 肽及其在治疗与突变型p53相关的疾病、病症或病况中的用途

Also Published As

Publication number Publication date
JP2019214573A (ja) 2019-12-19
RU2693487C2 (ru) 2019-07-03
AU2016200713B2 (en) 2017-02-02
US11028127B2 (en) 2021-06-08
JP6554099B2 (ja) 2019-07-31
ES2795982T3 (es) 2020-11-25
US20200095282A1 (en) 2020-03-26
US9856289B2 (en) 2018-01-02
US10550152B2 (en) 2020-02-04
US20160215019A1 (en) 2016-07-28
EP3030571B1 (en) 2020-03-18
HUE049292T2 (hu) 2020-09-28
IL268355A (en) 2019-09-26
IL243944B (en) 2019-08-29
AU2016200713A1 (en) 2016-05-19
IL243944A0 (en) 2016-04-21
AU2017202806B2 (en) 2018-04-05
CN105579464B (zh) 2021-01-26
CA2920147A1 (en) 2015-02-12
US10336789B2 (en) 2019-07-02
AU2017202806A1 (en) 2017-05-18
EP3030571A4 (en) 2017-05-10
JP2016527891A (ja) 2016-09-15
RU2019119609A3 (https=) 2019-12-30
RU2016106583A (ru) 2017-08-30
CA2920147C (en) 2022-09-20
HK1219742A1 (en) 2017-04-13
EP3030571A1 (en) 2016-06-15
RU2721423C2 (ru) 2020-05-19
WO2015019318A1 (en) 2015-02-12
US20190315804A1 (en) 2019-10-17
RU2016106583A3 (https=) 2018-03-29
RU2019119609A (ru) 2019-08-07
US20180057533A1 (en) 2018-03-01
CN105579464A (zh) 2016-05-11

Similar Documents

Publication Publication Date Title
BR112016002721A2 (pt) peptídeos capazes de reativar p53 mutantes
IL268576A (en) Systems, catheters, and related methods for mapping, minimizing, and treating cardiac fibrillation
IL283432A (en) Compositions, methods and systems for the treatment of cutaneous disorders
IL260269A (en) Immune effector cell therapies with enhanced efficacy
IL257486A (en) Methods and compositions for treating a proprotein convertase subtilisin kexin (pcsk9) gene-associated disorder
BR112012024382A2 (pt) agentes que induzem apoptose para o tratamento de câncer e doenças imunes e autoimunesças
HRP20181109T1 (hr) Spojevi biarila korisni za liječenje ljudskih bolesti u onkologiji, neurologiji i imunologiji
LT3253865T (lt) Metodai, skirti sustiprinti terapinių imuninių ląstelių veiksmingumą
CO6950477A2 (es) Agentes inductores de la apoptosis que pueden usarse para tratar el cáncer y las enfermedades inmunes y autoinmunes
HUE054634T2 (hu) Szelektív génterápiás kifejezõ rendszer
PT2970512T (pt) Proteínas de fusão imunomoduladoras e métodos para produção das mesmas
SG11201506069RA (en) Peptides for skin rejuvenation and methods of using the same
BR112016010224A2 (pt) combinações de inibidores do ponto de verificação e produtos terapêuticos para tratar o câncer.
DK3494997T3 (da) Inducerbare dna-bindende proteiner og værktøjer til genomperturbation samt anvendelser deraf
DK3461491T3 (da) Forbedret adoptiv celleterapi
MX375524B (es) Anticuerpos anti-axl.
EP3003486A4 (en) Vitamin d receptor agonists to treat diseases involving cxcl12 activity
PT2953634T (pt) Métodos de expansão ou depleção das células t reguladoras
EP3228626A4 (en) Peptide having activity to improve skin condition and use thereof
MX2016005956A (es) Anticuerpos especificos para fcrn.
HUE051632T2 (hu) Betegségek kezelésére szolgáló készítmények és eljárások
MX2015013447A (es) Polipeptidos que tienen actividad de la fosfolipasa a y polinucleotidos que los codifican.
DK3299453T3 (da) Celleterapi med polariserede makrofager til vævsregenerering
PT3511004T (pt) Preparações combinadas para o tratamento de cancro
PT3145709T (pt) Forro para mobiliário estofado

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B08G Application fees: restoration [chapter 8.7 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.